Yi Ke, Yang LingYun, Lan Zhu, Xi MingRong
Department of Gynecology and Obstetrics, The West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province 610000, China.
Department of Gynecology and Obstetrics, The West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province 610000, China.
Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:42-8. doi: 10.1016/j.ejogrb.2016.01.010. Epub 2016 Jan 21.
Endometriosis is a chronic, inflammatory, estrogen dependent disease. Genetic variation of estrogen biosynthesis and metabolic genes is associated with the risk of endometriosis. The CYP19 gene, encoding aromatase, plays an important role in the conversion of androgens to estrogens. Polymorphisms in the CYP19 gene are associated with circulating estrogen levels and estrogen/testosterone ratio. The aim of present study is to evaluate the impact of the CYP19 rs10046 polymorphism on endometriosis risk.
Embase, PubMed and other databases were searched for eligible case-control studies. A fixed-effects or random effects model was appropriately selected to calculate the pooled odds ratios (ORs).
A total of 8 case-control studies including 993 cases and 1956 controls were available. Overall, the pooled results indicated that CYP19 rs10046 polymorphism was not associated with endometriosis risk (for heterozygous CC vs. CT carriers OR=1.00, 95% CI: 0.82-1.21; for homozygous CC vs. TT carriers OR=1.06, 95% CI: 0.83-1.35; allele contrast C vs. T OR=1.01, 95% CI: 0.90-1.14; dominant model CC vs. CT+TT OR=1.02, 95% CI: 0.85-1.23; recessive model CC+CT vs. TT OR=1.05, 95% CI: 0.85-1.30). Heterogeneity among studies was founded in dominant model and allele contrast. Galbraith plot analyses were performed to assess the source of heterogeneity and one study was found to be contributor of heterogeneity. The heterogeneity decreased significantly after excluding that study.
Present meta-analysis reveals that CYP19 rs10046 polymorphism may be not correlated to endometriosis risk.
子宫内膜异位症是一种慢性、炎症性、雌激素依赖性疾病。雌激素生物合成和代谢基因的遗传变异与子宫内膜异位症的风险相关。编码芳香化酶的CYP19基因在雄激素向雌激素的转化中起重要作用。CYP19基因多态性与循环雌激素水平和雌激素/睾酮比值相关。本研究的目的是评估CYP19 rs10046多态性对子宫内膜异位症风险的影响。
检索Embase、PubMed和其他数据库以查找符合条件的病例对照研究。适当选择固定效应或随机效应模型来计算合并比值比（OR）。
共有8项病例对照研究，包括993例病例和1956例对照。总体而言，合并结果表明CYP19 rs10046多态性与子宫内膜异位症风险无关（杂合子CC与CT携带者相比，OR = 1.00，95% CI：0.82 - 1.21；纯合子CC与TT携带者相比，OR = 1.06，95% CI：0.83 - 1.35；等位基因对比C与T，OR = 1.01，95% CI：0.90 - 1.14；显性模型CC与CT + TT相比，OR = 1.02，95% CI：0.85 - 1.23；隐性模型CC + CT与TT相比，OR = 1.05，95% CI：0.85 - 1.30）。在显性模型和等位基因对比中发现研究间存在异质性。进行了Galbraith图分析以评估异质性来源，发现一项研究是异质性的来源。排除该研究后，异质性显著降低。
目前的荟萃分析表明CYP19 rs10046多态性可能与子宫内膜异位症风险无关。
